M
Michael J. Rybak
Researcher at Eugene Applebaum College of Pharmacy and Health Sciences
Publications - 454
Citations - 28036
Michael J. Rybak is an academic researcher from Eugene Applebaum College of Pharmacy and Health Sciences. The author has contributed to research in topics: Vancomycin & Daptomycin. The author has an hindex of 77, co-authored 420 publications receiving 24816 citations. Previous affiliations of Michael J. Rybak include Wayne State University & Detroit Medical Center.
Papers
More filters
Journal ArticleDOI
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
Catherine Liu,Arnold S. Bayer,Sara E. Cosgrove,Robert S. Daum,Scott K. Fridkin,Rachel J. Gorwitz,Sheldon L. Kaplan,Adolf W. Karchmer,Donald P. Levine,Barbara E. Murray,Michael J. Rybak,Henry F. Chambers +11 more
TL;DR: These guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system infections.
Journal ArticleDOI
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association
Larry M. Baddour,Walter R. Wilson,Arnold S. Bayer,Vance G. Fowler,Imad M. Tleyjeh,Michael J. Rybak,Bruno Baršić,Peter B. Lockhart,Michael H. Gewitz,Matthew E. Levison,Ann F. Bolger,James M. Steckelberg,Robert S. Baltimore,Anne M. Fink,Patrick T. O'Gara,Kathryn A. Taubert +15 more
TL;DR: The recommendations provided in this document are intended to assist in the management of this uncommon but potentially deadly infection and must be used to support and not supplant decisions in individual patient management.
Journal ArticleDOI
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
TL;DR: Vancomycin is a glycopeptide antibiotic that is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive streptococcus aureus infections.
Journal ArticleDOI
Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
Michael J. Rybak,Ben M. Lomaestro,John C. Rotschafer,Robert C. Moellering,Willam A. Craig,Marianne Billeter,Joseph R. Dalovisio,Donald P. Levine +7 more
TL;DR: A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomYcin therapy.
Journal ArticleDOI
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
TL;DR: The pharmacokinetic and pharmacodynamic data related to vancomycin are reviewed and such clinical issues as toxicities and serum concentration monitoring are discussed.